Full Press Release Details
Nevro Appoints Dr. Brad Vale to its Board of Directors
Menlo Park, Calif., March 2, 2015 - Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based
neuromodulation platform for the treatment of chronic pain, today announced that Brad Vale, PhD, DVM, former Head of Johnson & Johnson Development Company (JJDC), has been appointed to its Board of Directors, effective March 1, 2015.
Dr. Vale has over 30 years of experience in developing, commercializing and investing in innovative medical devices. He has extensive experience in
medical device research and development, including blood-compatible polymers, lasers, microsurgery, novel tissue closure, and hyaluronic acid for adhesion prevention.
We are delighted to add Dr. Vale, a medical device industry leader with significant strategic business experience in market changing technologies
and companies, to our board, said Michael DeMane, Chairman and Chief Executive Officer. Brad s leadership, experience and insights have been renowned in Silicon Valley for over two decades and they are great assets as we further our
mission of improving the quality of life of those afflicted with debilitating chronic pain.
It is an honor to join an organization committed
to providing life-changing treatment for patients suffering from chronic pain, said Dr. Vale. Nevro is emerging as a leader in the spinal cord stimulation field, and I am thrilled to join the company s board of directors at
this exciting stage of development.
Dr. Vale joined JJDC in 1992 and in 1997 moved to California to establish the Silicon Valley office. Since
joining JJDC, he has invested in over 30 companies. In 2008, Dr. Vale was appointed to the position of Vice President, Head of Venture Investments. In 2012, Dr. Vale was named Head of JJDC. Prior to joining JJDC, Dr. Vale supported
Johnson & Johnson s medical device businesses at the Corporate Office of Science and Technology. From 1982 to 1989, he was at Ethicon, Inc., a Johnson & Johnson subsidiary, working on preclinical studies, new business
development, and a coronary artery bypass graft internal venture.
In connection with Dr. Vale s appointment, Peter T. Bisgaard, Partner at Novo
Ventures, stepped off the Board of Directors at Nevro. Peter has been a significant contributor toward the successful transition of Nevro to a public company and his extensive expertise growing businesses in the medical technology sector has
been valuable, said Michael DeMane, Chairman and Chief Executive Officer. We are thankful for his contributions to the company during his tenure on the board.
Headquartered in Menlo Park, California, Nevro is a medical device company focused on providing innovative products that improve the quality of life of
patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the
treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro s proprietary HF10 therapy. In the United States, the Senza system is limited by federal law to investigational use only. Senza, HF10, Nevro and the
Nevro logo are trademarks of Nevro.
Investor Relations Contact: